The nearly doubled median OS is a strong efficacy signal for gotistobart in a difficult-to-treat population. Traders should watch for updates from the pivotal stage 2 of PRESERVE-003 and any regulatory interactions. Positive data could significantly de-risk the asset and support BioNTech's oncology pipeline beyond COVID.
Drug in focus
BNTX drug pipeline →gotistobart
● Neutral Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- At least 2-4 years away from potential approval, assuming positive Phase 3 data leads to regulatory filing. The PRESERVE-003 Phase 3 trial is ongoing with updated OS data due Sept 2026, but no regulatory submission has been announced.
- Next catalyst
- None dated
What to watchThe key near-term catalyst is the WCLC 2026 conference (Sept 12-15, 2026), where updated overall survival data from the Phase 3 PRESERVE-003 trial of gotistobart in squamous NSCLC will be presented. Positive data could drive BNTX shares higher, but gotistobart is one of several late-stage assets in BioNTech's broad pipeline, so the stock impact is unlikely to be binary.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 14 $98.86entry
- T+1 · 2mo ago −2.19%α −1.74% · $96.69
- T+5 · 8w ago −0.87%α −0.98% · $98.00
- T+20 · 5w ago −3.05%α −5.32% · $95.84
- T+45 · todayOpen
- T+60 · in 21d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioNTech and OncoC4 announced positive median overall survival (OS) data from stage 1 of the PRESERVE-003 Phase 3 trial for gotistobart in squamous NSCLC patients who progressed on prior immunotherapy and chemotherapy. Gotistobart nearly doubled median OS to 18.5 months vs 10.0 months for docetaxel (HR: 0.56, p=0.0295), a statistically significant and clinically meaningful result. The data were presented at WCLC 2026 and support the ongoing pivotal stage 2 of the trial.
Key Facts
- Gotistobart showed median OS of 18.5 months vs 10.0 months for docetaxel (HR: 0.56, p=0.0295)
- Data from non-pivotal stage 1 of PRESERVE-003 Phase 3 trial in squamous NSCLC patients after prior immunotherapy and chemotherapy
- Pivotal stage 2 of PRESERVE-003 is ongoing at >160 sites globally
- Gotistobart received Fast Track Designation from FDA (2022) and Orphan Drug Designation for squamous NSCLC (2025)
- Safety profile manageable: Grade ≥3 treatment-related AEs in 44.4% (gotistobart) vs 48.8% (docetaxel)
Financial Impact
Potential multi-billion dollar peak sales opportunity if approved in second-line squamous NSCLC, a large market with limited options
Risk Factors
- Stage 1 data is non-pivotal; pivotal stage 2 results are needed for registration
- Competition from other CTLA-4 and novel immunotherapies in NSCLC
- Regulatory approval not guaranteed; safety and manufacturing reviews remain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3360734 |
Track record
38 reports on BNTX
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 15 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.60 −1.85% settles Feb 8
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.60 −1.52% settles Feb 1
- Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.60 −3.96% settles Jan 27
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
- Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
- Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
- Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
- Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.60 −4.54% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers